港股通创新药阶段新低！资金坚定逆行，520880单日吸金超7500万元，基金份额创上市新高！

Core Viewpoint - The recent data indicates a significant adjustment in the sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping 3.32% to a five-month low, while over 75 million yuan was invested in the fund, marking a continuous inflow of over 200 million yuan in the past six days [1][9]. Fund Performance - The latest share count for the Hong Kong Stock Connect Innovative Drug ETF (520880) reached 4.148 billion shares, a record high since its launch, with the fund size at 2.165 billion yuan, also at a historical peak [4][11]. Market Dynamics - The fund's recent inflow is attributed to its value proposition, as the underlying index has seen a 21.56% pullback since early September, suggesting a favorable time for medium to long-term investment in core innovative drug assets [3][13]. - The National Healthcare Security Administration emphasized the importance of promoting innovative drug insurance coverage, encouraging commercial health insurance to include more reasonable medical expenses outside the basic insurance catalog [3][13]. Sector Outlook - Despite recent fluctuations in sentiment, the outlook for the innovative drug industry remains positive, with expectations for increased global competitiveness, successful international expansion, and commercial profitability by Q1 2026 [3][13]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted for its unique advantages, including a pure focus on innovative drug companies, a significant weight of over 72% in leading firms, and controlled risks through the reduction of illiquid stocks [5][6][13]. Index Composition - The top ten holdings in the ETF account for 72.57% of the total weight, showcasing the dominance of leading companies in the innovative drug sector [7][14].